![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, May 21, 2014 3:47:27 PM
- 30 months of funding
- 1 year away from trials
- 40 employees at ximedica working on this product
- 20 + medical experts say the video is better than state of art
- John currently talking about partnerships/sales in Europe
- CFO - $650k monthly burn rate
- CFO - Upto $80MM in Warrant funding to fund sales and post commercialization.
My opinions:
1) 50 million warrants though could dilute and not cause PPS appreciation like we expect
2) Mgmt is now less focused on PPS and more focused on product (I'm okay with this)
3) No Reverse Split (they didn't know what it was or why they would do it) - also no thinking currently of Nasdaq uplift.
Overall I would call this a Hold/Buy, as in, hold and buy more on dips. I can see this being a $800MM dollar company next year at the same time, and with say 120mm shares outstanding, that's about $6-$7 per share.
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM